{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-25-000064","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.676558+00:00","generated_at":"2026-05-16T22:11:59.588710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026","bullets":["Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.","Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.","Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.","R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.","Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-25-000064","json":"https://secwatch.observer/filing/0001055726-25-000064.json","markdown":"https://secwatch.observer/filing/0001055726-25-000064.md","text":"https://secwatch.observer/filing/0001055726-25-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/0001055726-25-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/ino-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:11:59.588710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}